The immune response in tuberculosis

Annual Review of Immunology

Volumn 31, Issue , 2013, Pages 475-527

  O'Garra, Anne ^a,c   Redford, Paul S ^a   McNab, Finlay W ^a   Bloom, Chloe I ^a   Wilkinson, Robert J ^a,b,c,d   Berry, Matthew P R ^a,e  

^a Division of Immunoregulation   (United Kingdom)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Cytokines; Infection; M. tuberculosis; Pathogenesis; Protection

Indexed keywords

ADAPTOR PROTEIN; CD1 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; MATRIX METALLOPROTEINASE; PATTERN RECOGNITION RECEPTOR; TUMOR NECROSIS FACTOR; VITAMIN D;

ADAPTIVE IMMUNITY; AEROSOL; APOPTOSIS; B LYMPHOCYTE; BACTERIAL STRAIN; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; DISEASE PREDISPOSITION; GENE MUTATION; GENETIC SUSCEPTIBILITY; GRANULOMA; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; LYMPH NODE; MACROPHAGE; MYCOBACTERIUM TUBERCULOSIS; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL; TRANSCRIPTOMICS; VACCINATION;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84875498895     PISSN: 07320582     EISSN: 15453278     Source Type: Book Series    
DOI: 10.1146/annurev-immunol-032712-095939     Document Type: Review

References (373)

1. WHO. 2012. World Health Organization: Tuberculosis-Global Facts 2011/2102. Geneva:WHO Stop TB Dep. http://www.who.int/tb/publications/2011/ factsheet-tb-2011.pdf
2. Young DB, Perkins MD, Duncan K, Barry CE 3rd. 2008. Confronting the scientific obstacles to global control of tuberculosis. J. Clin. Investig. 118:1255-65
3. Koch R. 1882. The etiology of tuberculosis. Berl. Klin. Wochenschr. 15:221-30
4. Harisinghani MG, McLoud TC, Shepard JA, Ko JP, Shroff MM, Mueller PR. 2000. Tuberculosis from head to toe. Radiographics 20:449-70
5. CCDC. 2007. Center for Communicable Disease Control and Prevention. Reported Tuberculosis in the United States, 2007. Atlanta, GA: US Dep. Health Hum. Serv.
6. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. 1999. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282:677-86
7. Comstock GW, Livesay VT, Woolpert SF. 1974. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am. J. Epidemiol. 99:131-38
8. Vynnycky E, Fine PE. 2000. Lifetime risks, incubation period, and serial interval of tuberculosis. Am. J. Epidemiol. 152:247-63
9. Kaufmann SH. 2012. Tuberculosis vaccine development: strength lies in tenacity. Trends Immunol. 33:373-79
10. McShane H, Jacobs WR, Fine PE, Reed SG, McMurray DN, et al. 2012. BCG: myths, realities, and the need for alternative vaccine strategies. Tuberculosis 92:283-88
11. Cooper AM. 2009. Cell-mediated immune responses in tuberculosis. Annu. Rev. Immunol. 27:393-422
12. Flynn JL, Chan J. 2001. Immunology of tuberculosis. Annu. Rev. Immunol. 19:93-129
13. North RJ, Jung YJ. 2004. Immunity to tuberculosis. Annu. Rev. Immunol. 22:599-623
14. Alcais A, Fieschi C, Abel L, Casanova JL. 2005. Tuberculosis in children and adults: two distinct genetic diseases. J. Exp. Med. 202:1617-21
15. Alcais A, Quintana-Murci L, Thaler DS, Schurr E, Abel L, Casanova JL. 2010. Life-threatening infectious diseases of childhood: single-gene inborn errors of immunity? Ann. N.Y. Acad. Sci. 1214:18-33
16. Flynn JL, GoldsteinMM, Chan J, TrieboldKJ, Pfeffer K, et al. 1995. Tumor necrosis factor-αis required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2:561-72
17. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, et al. 2001. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med. 345:1098-104
18. Barry CE 3rd, Boshoff HI, Dartois V, Dick T, Ehrt S, et al. 2009. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 7:845-55
19. Kagina BM, Abel B, Scriba TJ, Hughes EJ, Keyser A, et al. 2010. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am. J. Respir. Crit. CareMed. 182:1073-79
20. Apt A, Kramnik I. 2009. Man and mouse TB: contradictions and solutions. Tuberculosis 89:195-98
21. Fortin A, Abel L, Casanova JL, Gros P. 2007. Host genetics of mycobacterial diseases in mice and men: forward genetic studies of BCG-osis and tuberculosis. Annu. Rev. Genomics Hum. Genet. 8:163-92
22. Gagneux S. 2012. Host-pathogen coevolution in human tuberculosis. Philos. Trans. R. Soc. Lond. Ser. B 367:850-59
23. Gagneux S, DeRiemer K, Van T, Kato-Maeda M, de Jong BC, et al. 2006. Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 103:2869-73
24. Manca C, Tsenova L, Bergtold A, Freeman S, Tovey M, et al. 2001. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-α/β. Proc. Natl. Acad. Sci. USA 98:5752-57
25. NicolMP, WilkinsonRJ. 2008. The clinical consequences of strain diversity in Mycobacterium tuberculosis. Trans. R. Soc. Trop. Med. Hyg. 102:955-65
26. de Jong BC, Hill PC, Aiken A, Awine T, Antonio M, et al. 2008. Progression to active tuberculosis, but not transmission, varies by Mycobacterium tuberculosis lineage in The Gambia. J. Infect. Dis. 198:1037-43
27. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. 2003. Tuberculosis. Lancet 362:887-99
28. Brandli O. 1998. The clinical presentation of tuberculosis. Respir. Int. Rev. Thorac. Dis. 65:97-105
29. Wyngarden JB. 1988. Cecil Textbook of Medicine. Philadelphia: W.B. Saunders
30. Storla DG, Yimer S, Bjune GA. 2008. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health 8:15
31. Steingart KR, Henry M, Ng V, Hopewell PC, Ramsay A, et al. 2006. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect. Dis. 6:570-81
32. PfyfferGE, Cieslak C, WelscherHM, KisslingP, Rusch-Gerdes S. 1997. Rapid detection of mycobacteria in clinical specimens by using the automatedBACTEC9000MBsystem and comparisonwith radiometric and solid-culture systems. J. Clin. Microbiol. 35:2229-34
33. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, et al. 2010. Rapid molecular detection of tuberculosis and rifampin resistance. N. Engl. J. Med. 363:1005-15
34. Stop TB Partnersh. 2010. The Global Plan to Stop TB 2011-2015. Geneva:WHO
35. Schoch OD, Rieder P, Tueller C, Altpeter E, Zellweger JP, et al. 2007. Diagnostic yield of sputum, induced sputum, and bronchoscopy after radiologic tuberculosis screening. Am. J. Respir. Crit. Care Med. 175:80-86
36. Millen SJ, Uys PW, Hargrove J, van Helden PD, Williams BG. 2008. The effect of diagnostic delays on the drop-out rate and the total delay to diagnosis of tuberculosis. PLoS ONE 3:e1933
37. Fox W, Ellard GA, Mitchison DA. 1999. Studies on the treatment of tuberculosis undertaken by the BritishMedical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int. J. Tuberc. Lung Dis. 3(Suppl.):S231-79
38. Natl. Inst. Health Clin. Excell., Natl. Collab. Cent. Chronic Cond. 2006. Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control. London: R. Coll. Phys.
39. Med. Res. Counc. 1988. Management and outcome of pulmonary tuberculosis in adults notified in England and Wales in 1983. Medical Research Council Tuberculosis and Chest Diseases Unit. Thorax 43:591-98
40. Mitchison DA. 1993. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am. Rev. Respir. Dis. 147:1062-63
41. Horne DJ, Royce SE, Gooze L, Narita M, Hopewell PC, et al. 2010. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect. Dis. 10:387-94
42. Walzl G, Ronacher K, HanekomW, Scriba TJ, Zumla A. 2011. Immunological biomarkers of tuberculosis. Nat. Rev. Immunol. 11:343-54
43. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, et al. 2003. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163:1009-21
44. Gomez JE, McKinney JD. 2004. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis 84:29-44
45. Lillebaek T, Dirksen A, Vynnycky E, Baess I, Thomsen VO, Andersen AB. 2003. Stability of DNA patterns and evidence of Mycobacterium tuberculosis reactivation occurring decades after the initial infection. J. Infect. Dis. 188:1032-39
46. Chan J, Flynn J. 2004. The immunological aspects of latency in tuberculosis. Clin. Immunol. 110:2-12
47. Vandiviere HM, Loring WE, Melvin I, Willis S. 1956. The treated pulmonary lesion and its tubercle bacillus. II. The death and resurrection. Am. J. Med. Sci. 232:30-37
48. Lin PL, Flynn JL. 2010. Understanding latent tuberculosis: a moving target. J. Immunol. 185:15-22
49. YoungDB, Gideon HP, WilkinsonRJ. 2009. Eliminating latent tuberculosis. Trends Microbiol. 17:183-88
50. Pirquet V. 1907. Frequency of tuberculosis in childhood. JAMA 52:675-78
51. Mantoux MC. 1912. La voie intradermique en tubercalinotherapie. Presse Med. 20:146-48
52. Reichman LB. 1979. Tuberculin skin testing. The state of the art. Chest 76:764-70
53. Holden M, Dubin MR, Diamond PH. 1971. Frequency of negative intermediate-strength tuberculin sensitivity in patients with active tuberculosis. N. Engl. J. Med. 285:1506-9
54. Richeldi L. 2006. An update on the diagnosis of tuberculosis infection. Am. J. Respir. Crit. Care Med. 174:736-42
55. Andersen P, Doherty TM. 2005. The success and failure of BCG-implications for a novel tuberculosis vaccine. Nat. Rev. Microbiol. 3:656-62
56. Horsburgh CR Jr. 2004. Priorities for the treatment of latent tuberculosis infection in the United States. N. Engl. J. Med. 350:2060-67
57. Van Rhijn I, Nguyen TK, Michel A, Cooper D, Govaerts M, et al. 2009. Low cross-reactivity of T-cell responses against lipids from Mycobacterium bovis and M. avium paratuberculosis during natural infection. Eur. J. Immunol. 39:3031-41
58. Harboe M, Oettinger T, Wiker HG, Rosenkrands I, Andersen P. 1996. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect. Immun. 64:16-22
59. Jereb J, Etkind SC, Joglar OT, MooreM, Taylor Z. 2003. Tuberculosis contact investigations: outcomes in selected areas of the United States, 1999. Int. J. Tuberc. Lung Dis. 7:S384-90
60. Marks SM, Taylor Z, Qualls NL, Shrestha-Kuwahara RJ, Wilce MA, Nguyen CH. 2000. Outcomes of contact investigations of infectious tuberculosis patients. Am. J. Respir. Crit. CareMed. 162:2033-38
61. Styblo K. 1980. Recent advances in epidemiological research in tuberculosis. Adv. Tuberc. Res. 20:1-63
62. Cobat A, Gallant CJ, Simkin L, Black GF, Stanley K, et al. 2010. High heritability of antimycobacterial immunity in an area of hyperendemicity for tuberculosis disease. J. Infect. Dis. 201:15-19
63. Cobat A, Gallant CJ, Simkin L, Black GF, Stanley K, et al. 2009. Two loci control tuberculin skin test reactivity in an area hyperendemic for tuberculosis. J. Exp. Med. 206:2583-91
64. Medlar EM. 1948. The pathogenesis of minimal pulmonary tuberculosis; a study of 1, 225 necropsies in cases of sudden and unexpected death. Am. Rev. Tuberc. 58:583-611
65. Capuano SV, Croix DA, Pawar S, Zinovik A, Myers A, et al. 2003. Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect. Immun. 71:5831-44
66. Fennelly KP, Jones-Lopez EC, Ayakaka I, Kim S, Menyha H, et al. 2012. Variability of infectious aerosols produced during coughing by patients with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 186:450-57
67. Escombe AR, Oeser C, Gilman RH, Navincopa M, Ticona E, et al. 2007. The detection of airborne transmission of tuberculosis from HIV-infected patients, using an in vivo air samplingmodel. Clin. Infect. Dis. 44:1349-57
68. Mack U, Migliori GB, SesterM, Rieder HL, Ehlers S, et al. 2009. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur. Respir. J. 33:956-73
69. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, et al. 1999. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286:531-37
70. Bonnefoi H, Underhill C, Iggo R, Cameron D. 2009. Predictive signatures for chemotherapy sensitivity in breast cancer: are they ready for use in the clinic? Eur. J. Cancer 45:1733-43
71. Pascual V, Chaussabel D, Banchereau J. 2010. A genomic approach to human autoimmune diseases. Annu. Rev. Immunol. 28:535-71
72. Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, et al. 2010. An interferon-inducible neutrophildriven blood transcriptional signature in human tuberculosis. Nature 466:973-77
73. Bloom CI, Graham CM, Berry MP, Wilkinson KA, Oni T, et al. 2012. Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy. PLoS ONE 7:e46191
74. Ernst JD, HanekomW, Hawn T, Kampmann B, Rengarajan J. 2012. Meeting report: The International Conference on Human Immunity to Tuberculosis. Tuberculosis 92:440-44
75. Maertzdorf J, Repsilber D, Parida SK, Stanley K, Roberts T, et al. 2011. Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun. 12:15-22
76. Ottenhoff TH, Dass RH, Yang N, ZhangMM, WongHE, et al. 2012. Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis. PLoS ONE 7:e45839
77. Cliff JM, Lee JS, Constantinou N, Cho JE, ClarkTG, et al. 2013. Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. J. Infect. Dis. 207:18-29
78. Jacobsen M, Repsilber D, Kleinsteuber K, Gutschmidt A, Schommer-Leitner S, et al. 2011. Suppressor of cytokine signaling-3 is affected in T-cells from tuberculosis TB patients. Clin. Microbiol. Infect. 17:1323-31
79. Chaussabel D, Allman W, Mejias A, Chung W, Bennett L, et al. 2005. Analysis of significance patterns identifies ubiquitous and disease-specific gene-expression signatures in patient peripheral blood leukocytes. Ann. N.Y. Acad. Sci. 1062:146-54
80. Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, et al. 2008. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 29:150-64
81. Koth LL, Solberg OD, Peng JC, Bhakta NR, Nguyen CP, Woodruff PG. 2011. Sarcoidosis blood transcriptome reflects lung inflammation and overlaps with tuberculosis. Am. J. Respir. Crit. CareMed. 184:1153-63
82. Maertzdorf J, Weiner J 3rd, Mollenkopf HJ, Network T, Bauer T, et al. 2012. Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proc. Natl. Acad. Sci. USA 109:7853-58
83. Iannuzzi MC, Rybicki BA, Teirstein AS. 2007. Sarcoidosis. N. Engl. J. Med. 357:2153-65
84. Medina E, North RJ. 1998. Resistance ranking of some common inbred mouse strains to Mycobacterium tuberculosis and relationship tomajor histocompatibility complex haplotype and Nramp1 genotype. Immunology 93:270-74
85. Via LE, Lin PL, Ray SM, Carrillo J, Allen SS, et al. 2008. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect. Immun. 76:2333-40
86. McMurray DN. 2001. Disease model: pulmonary tuberculosis. Trends Mol. Med. 7:135-37
87. Cooper AM, Magram J, Ferrante J, Orme IM. 1997. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J. Exp. Med. 186:39-45
88. Flynn JL, Chan J, TrieboldKJ, Dalton DK, Stewart TA, Bloom BR. 1993. An essential role for interferon γin resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178:2249-54
89. Orme IM, Andersen P, Boom WH. 1993. T cell response to Mycobacterium tuberculosis. J. Infect. Dis. 167:1481-97
90. Geldmacher C, Ngwenyama N, Schuetz A, Petrovas C, Reither K, et al. 2010. Preferential infection and depletion of Mycobacterium tuberculosis-specific CD4 T cells after HIV-1 infection. J. Exp. Med. 207:2869-81
91. Geldmacher C, Schuetz A, Ngwenyama N, Casazza JP, Sanga E, et al. 2008. Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection. J. Infect. Dis. 198:1590-98
92. Chackerian AA, Behar SM. 2003. Susceptibility to Mycobacterium tuberculosis: lessons from inbred strains of mice. Tuberculosis 83:279-85
93. Marquis JF, Nantel A, LaCourse R, Ryan L, NorthRJ, Gros P. 2008. Fibrotic response as a distinguishing feature of resistance and susceptibility to pulmonary infection with Mycobacterium tuberculosis in mice. Infect. Immun. 76:78-88
94. Mitsos LM, Cardon LR, Fortin A, Ryan L, LaCourse R, et al. 2000. Genetic control of susceptibility to infection with Mycobacterium tuberculosis in mice. Genes Immun. 1:467-77
95. Keller C, Hoffmann R, Lang R, Brandau S, Hermann C, Ehlers S. 2006. Genetically determined susceptibility to tuberculosis in mice causally involves accelerated and enhanced recruitment of granulocytes. Infect. Immun. 74:4295-309
96. Manabe YC, Kesavan AK, Lopez-Molina J, Hatem CL, BrooksM, et al. 2008. The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome. Tuberculosis 88:187-96
97. Subbian S, Tsenova L, O'Brien P, Yang G, Koo MS, et al. 2011. Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology. Am. J. Pathol. 179:289-301
98. Subbian S, Tsenova L, Yang G, O'Brien P, Parsons S, et al. 2011. Chronic pulmonary cavitary tuberculosis in rabbits: a failed host immune response. Open Biol. 1:110016
99. Manca C, Tsenova L, Freeman S, Barczak AK, Tovey M, et al. 2005. Hypervirulent M. tuberculosis W/Beijing strains upregulate type I IFNs and increase expression of negative regulators of the Jak-Stat pathway. J. Interferon Cytokine Res. 25:694-701
100. Lin PL, Rodgers M, Smith L, Bigbee M, Myers A, et al. 2009. Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect. Immun. 77:4631-42
101. Russell DG, Cardona PJ, Kim MJ, Allain S, Altare F. 2009. Foamy macrophages and the progression of the human tuberculosis granuloma. Nat. Immunol. 10:943-48
102. Peters W, Ernst JD. 2003. Mechanisms of cell recruitment in the immune response to Mycobacterium tuberculosis. Microbes Infect. 5:151-58
103. Egen JG, Rothfuchs AG, Feng CG, Horwitz MA, Sher A, Germain RN. 2011. Intravital imaging reveals limited antigen presentation and T cell effector function in mycobacterial granulomas. Immunity 34:807-19
104. Ulrichs T, Kosmiadi GA, Trusov V, Jorg S, Pradl L, et al. 2004. Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung. J. Pathol. 204:217-28
105. Hernandez-Pando R, Jeyanathan M, Mengistu G, Aguilar D, Orozco H, et al. 2000. Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection. Lancet 356:2133-38
106. Tsai MC, Chakravarty S, Zhu G, Xu J, Tanaka K, et al. 2006. Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension. Cell. Microbiol. 8:218-32
107. Reece ST, Loddenkemper C, Askew DJ, Zedler U, Schommer-Leitner S, et al. 2010. Serine protease activity contributes to control of Mycobacterium tuberculosis in hypoxic lung granulomas in mice. J. Clin. Investig. 120:3365-76
108. SaundersBM, Orme IM, Basaraba R. 2008. Immunopathology of tuberculosis. In Handbook of Tuberculosis: Immunology and Cell Biology, ed. SHE Kaufmann, WJ Britton, pp. 245-78. Germany: Wiley-VCH
109. Davis JM, Ramakrishnan L. 2009. The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell 136:37-49
110. Ramakrishnan L. 2012. Revisiting the role of the granuloma in tuberculosis. Nat. Rev. Immunol. 12:352-66
111. Tobin DM, Vary JC Jr, Ray JP, Walsh GS, Dunstan SJ, et al. 2010. The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell 140:717-30
112. Garton NJ, Waddell SJ, Sherratt AL, Lee SM, Smith RJ, et al. 2008. Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med. 5:e75
113. Schlesinger LS. 1996. Entry of Mycobacterium tuberculosis into mononuclear phagocytes. Curr. Top. Microbiol. Immunol. 215:71-96
114. Eruslanov EB, Lyadova IV, Kondratieva TK, Majorov KB, Scheglov IV, et al. 2005. Neutrophil responses to Mycobacterium tuberculosis infection in genetically susceptible and resistantmice. Infect. Immun. 73:1744-53
115. Eum SY, Kong JH, Hong MS, Lee YJ, Kim JH, et al. 2010. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 137:122-28
116. Wolf AJ, Linas B, Trevejo-Nunez GJ, Kincaid E, Tamura T, et al. 2007. Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo. J. Immunol. 179:2509-19
117. Lowe DM, Redford PS, Wilkinson RJ, O'Garra A, Martineau AR. 2012. Neutrophils in tuberculosis: friend or foe? Trends Immunol. 33:14-25
118. Castaneda-Delgado J, Hernandez-Pando R, Serrano CJ, Aguilar-Leon D, Le on-Contreras J, et al. 2010. Kinetics and cellular sources of cathelicidin during the course of experimental latent tuberculous infection and progressive pulmonary tuberculosis. Clin. Exp. Immunol. 161:542-50
119. FabriM, Stenger S, Shin DM, Yuk JM, Liu PT, et al. 2011. Vitamin D is required for IFN-γ-mediated antimicrobial activity of human macrophages. Sci. Transl. Med. 3:104ra2
120. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, et al. 2006. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311:1770-73
121. MartineauAR, Honecker FU, WilkinsonRJ, Griffiths CJ. 2007. VitaminDin the treatment of pulmonary tuberculosis. J. Steroid Biochem. Mol. Biol. 103:793-98
122. Martineau AR, Wilkinson KA, Newton SM, Floto RA, Norman AW, et al. 2007. IFN-γ-and TNFindependent vitamin D-inducible human suppression of mycobacteria: the role of cathelicidin LL-37. J. Immunol. 178:7190-98
123. Behar SM, Martin CJ, Booty MG, Nishimura T, Zhao X, et al. 2011. Apoptosis is an innate defense function of macrophages against Mycobacterium tuberculosis. Mucosal Immunol. 4:279-87
124. Cooper AM, Mayer-Barber KD, Sher A. 2011. Role of innate cytokines in mycobacterial infection. Mucosal Immunol. 4:252-60
125. Kleinnijenhuis J, Oosting M, Joosten LA, Netea MG, Van Crevel R. 2011. Innate immune recognition of Mycobacterium tuberculosis. Clin. Dev. Immunol. 2011:405310
126. Armstrong JA, Hart PD. 1971. Response of cultured macrophages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes. J. Exp. Med. 134:713-40
127. ColomboMI, GutierrezMG, Romano PS. 2006. The two faces of autophagy: Coxiella and Mycobacterium. Autophagy 2:162-64
128. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. 2004. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 119:753-66
129. Sturgill-Koszycki S, Schlesinger PH, Chakraborty P, Haddix PL, Collins HL, et al. 1994. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science 263:678-81
130. Armstrong JA, Hart PD. 1975. Phagosome-lysosome interactions in cultured macrophages infected with virulent tubercle bacilli. Reversal of the usual nonfusion pattern and observations on bacterial survival. J. Exp. Med. 142:1-16
131. Pieters J. 2008. Mycobacterium tuberculosis and the macrophage: maintaining a balance. Cell Host Microbe 3:399-407
132. Behar SM, Divangahi M, Remold HG. 2010. Evasion of innate immunity by Mycobacterium tuberculosis: is death an exit strategy? Nat. Rev. Microbiol. 8:668-74
133. Shafiani S, Tucker-Heard G, Kariyone A, Takatsu K, Urdahl KB. 2010. Pathogen-specific regulatory T cells delay the arrival of effector T cells in the lung during early tuberculosis. J. Exp. Med. 207:1409-20
134. Chackerian AA, Alt JM, Perera TV, Dascher CC, Behar SM. 2002. Dissemination of Mycobacterium tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity. Infect. Immun. 70:4501-9
135. Keane J, Remold HG, Kornfeld H. 2000. Virulent Mycobacterium tuberculosis strains evade apoptosis of infected alveolar macrophages. J. Immunol. 164:2016-20
136. KellyDM, ten BokumAM, O'Leary SM, O'Sullivan MP, Keane J. 2008. Bystandermacrophage apoptosis after Mycobacterium tuberculosis H37Ra infection. Infect. Immun. 76:351-60
137. Hinchey J, Lee S, Jeon BY, Basaraba RJ, Venkataswamy MM, et al. 2007. Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J. Clin. Investig. 117:2279-88
138. Velmurugan K, Chen B, Miller JL, Azogue S, Gurses S, et al. 2007. Mycobacterium tuberculosis nuoG is a virulence gene that inhibits apoptosis of infected host cells. PLoS Pathog. 3:e110
139. Martin CJ, Booty MG, Rosebrock TR, Nunes-Alves C, Desjardins DM, et al. 2012. Efferocytosis is an innate antibacterial mechanism. Cell Host Microbe 12:289-300
140. Liao X, Sluimer JC, Wang Y, Subramanian M, Brown K, et al. 2012. Macrophage autophagy plays a protective role in advanced atherosclerosis. Cell Metab. 15:545-53
141. BaficaA, Scanga CA, SerhanC, MachadoF, White S, et al. 2005. Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production. J. Clin. Investig. 115:1601-6
142. Chen M, Divangahi M, Gan H, Shin DS, Hong S, et al. 2008. Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. J. Exp. Med. 205:2791-801
143. Divangahi M, Desjardins D, Nunes-Alves C, Remold HG, Behar SM. 2010. Eicosanoid pathways regulate adaptive immunity to Mycobacterium tuberculosis. Nat. Immunol. 11:751-58
144. Abadie V, Badell E, Douillard P, Ensergueix D, Leenen PJ, et al. 2005. Neutrophils rapidly migrate via lymphatics after Mycobacterium bovis BCG intradermal vaccination and shuttle live bacilli to the draining lymph nodes. Blood 106:1843-50
145. Sutherland JS, Jeffries DJ, Donkor S, Walther B, Hill PC, et al. 2009. High granulocyte/lymphocyte ratio and paucity of NKT cells defines TB disease in a TB-endemic setting. Tuberculosis 89:398-404
146. Seiler P, Aichele P, Bandermann S, Hauser AE, Lu B, et al. 2003. Early granuloma formation after aerosol Mycobacterium tuberculosis infection is regulated by neutrophils via CXCR3-signaling chemokines. Eur. J. Immunol. 33:2676-86
147. Bandara A, Bremner S, Barker R, Packe G, Griffiths C, Martineau A. 2008. Neutrophilia in tuberculosis. Thorax 63(Suppl.):A111-17
148. Barnes PF, Leedom JM, Chan LS, Wong SF, Shah J, et al. 1988. Predictors of short-term prognosis in patients with pulmonary tuberculosis. J. Infect. Dis. 158:366-71
149. + T cells during Mycobacterium tuberculosis infection. J. Immunol. 186:7110-19
150. Blomgran R, Desvignes L, Briken V, Ernst JD. 2012. Mycobacterium tuberculosis inhibits neutrophil apoptosis, leading to delayed activation of naive CD4 T cells. Cell Host Microbe 11:81-90
151. Zhang X, Majlessi L, Deriaud E, Leclerc C, Lo-Man R. 2009. Coactivation of Syk kinase and MyD88 adaptor protein pathways by bacteria promotes regulatory properties of neutrophils. Immunity 31:761-71
152. Cruz A, Fraga AG, Fountain JJ, Rangel-Moreno J, Torrado E, et al. 2010. Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J. Exp. Med. 207:1609-16
153. Redford PS, Boonstra A, Read S, Pitt J, Graham C, et al. 2010. Enhanced protection to Mycobacterium tuberculosis infection in IL-10-deficient mice is accompanied by early and enhanced Th1 responses in the lung. Eur. J. Immunol. 40:2200-10
154. Nandi B, Behar SM. 2011. Regulation of neutrophils by interferon-γ limits lung inflammation during tuberculosis infection. J. Exp. Med. 208:2251-62
155. Bean AG, Roach DR, Briscoe H, France MP, KornerH, et al. 1999. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J. Immunol. 162:3504-11
156. Kaneko H, Yamada H, Mizuno S, Udagawa T, Kazumi Y, et al. 1999. Role of tumor necrosis factor-αin Mycobacterium-induced granuloma formation in tumor necrosis factor-α-deficient mice. Lab. Investig. 79:379-86
157. Botha T, Ryffel B. 2003. Reactivation of latent tuberculosis infection in TNF-deficient mice. J. Immunol. 171:3110-18
158. Chakravarty SD, Zhu G, Tsai MC, Mohan VP, Marino S, et al. 2008. Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs. Infect. Immun. 76:916-26
159. Mohan VP, Scanga CA, Yu K, Scott HM, Tanaka KE, et al. 2001. Effects of tumor necrosis factor α on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect. Immun. 69:1847-55
160. Harris J, Keane J. 2010. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin. Exp. Immunol. 161:1-9
161. Vassalli P. 1992. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 10:411-52
162. Pasparakis M, Alexopoulou L, Douni E, Kollias G. 1996. Tumour necrosis factors in immune regulation: everything that's interesting is. . .new! Cytokine Growth Factor Rev. 7:223-29
163. Roach DR, Briscoe H, Saunders B, France MP, Riminton S, BrittonWJ. 2001. Secreted lymphotoxin-α is essential for the control of an intracellular bacterial infection. J. Exp. Med. 193:239-46
164. Iliopoulos A, Psathakis K, Aslanidis S, Skagias L, Sfikakis PP. 2006. Tuberculosis and granuloma formation in patients receiving anti-TNF therapy. Int. J. Tuberc. Lung Dis. 10:588-90
165. Lin PL, Myers A, Smith L, Bigbee C, BigbeeM, et al. 2010. Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model. Arthritis Rheum. 62:340-50
166. Clay H, Volkman HE, Ramakrishnan L. 2008. Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. Immunity 29:283-94
167. Miller EA, Ernst JD. 2008. Illuminating the black box of TNF action in tuberculous granulomas. Immunity 29:175-77
168. Herb F, Thye T, Niemann S, Browne EN, Chinbuah MA, et al. 2008. ALOX5 variants associated with susceptibility to human pulmonary tuberculosis. Hum. Mol. Genet. 17:1052-60
169. Salgame P. 2011. MMPs in tuberculosis: granuloma creators and tissue destroyers. J. Clin. Investig. 121:1686-88
170. Elkington P, ShiomiT, Breen R, Nuttall RK, Ugarte-GilCA, et al. 2011. MMP-1 drives immunopathology in human tuberculosis and transgenic mice. J. Clin. Investig. 121:1827-33
171. Elkington PT, Nuttall RK, Boyle JJ, O'Kane CM, HorncastleDE, et al. 2005. Mycobacterium tuberculosis, but not vaccine BCG, specifically upregulates matrix metalloproteinase-1. Am. J. Respir. Crit. CareMed. 172:1596-604
172. Elkington PT, Ugarte-Gil CA, Friedland JS. 2011. Matrix metalloproteinases in tuberculosis. Eur. Respir. J. 38:456-64
173. Price NM, Farrar J, Tran TT, Nguyen TH, Tran TH, Friedland JS. 2001. Identification of a matrixdegrading phenotype in human tuberculosis in vitro and in vivo. J. Immunol. 166:4223-30
174. VolkmanHE, Pozos TC, Zheng J, Davis JM, Rawls JF, Ramakrishnan L. 2010. Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science 327:466-69
175. Walker NF, Clark SO, Oni T, AndreuN, Tezera L, et al. 2012. Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases. Am. J. Respir. Crit. CareMed. 185:989-97
176. Martineau AR, Timms PM, Bothamley GH, Hanifa Y, Islam K, et al. 2011. High-dose vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 377:242-50
177. Nursyam EW, Amin Z, Rumende CM. 2006. The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. Acta Med. Indones. 38:3-5
178. Martineau AR, Nhamoyebonde S, Oni T, Rangaka MX, Marais S, et al. 2011. Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa. Proc. Natl. Acad. Sci. USA 108:19013-17
179. Raghavan S, Alagarasu K, Selvaraj P. 2012. Immunogenetics of HIV and HIV associated tuberculosis. Tuberculosis 92:18-30
180. Rook GA, Steele J, Fraher L, Barker S, Karmali R, et al. 1986. Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology 57:159-63
181. Yuk JM, Shin DM, Lee HM, Yang CS, Jin HS, et al. 2009. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe 6:231-43
182. Berrington WR, Hawn TR. 2007. Mycobacterium tuberculosis, macrophages, and the innate immune response: does common variation matter? Immunol. Rev. 219:167-86
183. ReilingN, Ehlers S, Holscher C. 2008. MyDths and un-TOLLed truths: sensor, instructive and effector immunity to tuberculosis. Immunol. Lett. 116:15-23
184. Schafer G, Jacobs M, Wilkinson RJ, Brown GD. 2009. Non-opsonic recognition of Mycobacterium tuberculosis by phagocytes. J. Innate Immun. 1:231-43
185. Tanne A, Neyrolles O. 2011. C-type lectins in immunity to Mycobacterium tuberculosis. Front. Biosci. 3:1147-64
186. DivangahiM, Mostowy S, Coulombe F, Kozak R, Guillot L, et al. 2008. NOD2-deficient mice have impaired resistance to Mycobacterium tuberculosis infection through defective innate and adaptive immunity. J. Immunol. 181:7157-65
187. Tanne A, MaB, Boudou F, Tailleux L, Botella H, et al. 2009.AmurineDC-SIGNhomologue contributes to early host defense against Mycobacterium tuberculosis. J. Exp. Med. 206:2205-20
188. Caws M, Thwaites G, Dunstan S, Hawn TR, Lan NT, et al. 2008. The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis. PLoS Pathog. 4:e1000034
189. Fremond CM, Yeremeev V, Nicolle DM, Jacobs M, Quesniaux VF, Ryffel B. 2004. Fatal Mycobacterium tuberculosis infection despite adaptive immune response in the absence of MyD88. J. Clin. Investig. 114:1790-99
190. Scanga CA, Bafica A, Feng CG, Cheever AW, Hieny S, Sher A. 2004. MyD88-deficient mice display a profound loss in resistance to Mycobacterium tuberculosis associated with partially impaired Th1 cytokine and nitric oxide synthase 2 expression. Infect. Immun. 72:2400-4
191. Sugawara I, Yamada H, Mizuno S, Takeda K, Akira S. 2003. Mycobacterial infection inMyD88-deficient mice. Microbiol. Immunol. 47:841-47
192. Dorhoi A, Desel C, Yeremeev V, Pradl L, Brinkmann V, et al. 2010. The adaptor molecule CARD9 is essential for tuberculosis control. J. Exp. Med. 207:777-92
193. Juffermans NP, Florquin S, Camoglio L, Verbon A, Kolk AH, et al. 2000. Interleukin-1 signaling is essential for host defense during murine pulmonary tuberculosis. J. Infect. Dis. 182:902-8
194. Sugawara I, Yamada H, Hua S, Mizuno S. 2001. Role of interleukin (IL)-1 type 1 receptor in mycobacterial infection. Microbiol. Immunol. 45:743-50
195. Yamada H, Mizumo S, Horai R, Iwakura Y, Sugawara I. 2000. Protective role of interleukin-1 in mycobacterial infection in IL-1 α/βdouble- knockout mice. Lab. Investig. 80:759-67
196. Kleinnijenhuis J, Joosten LA, van de Veerdonk FL, Savage N, van Crevel R, et al. 2009. Transcriptional and inflammasome-mediated pathways for the induction of IL-1β production by Mycobacterium tuberculosis. Eur. J. Immunol. 39:1914-22
197. Fremond CM, Togbe D, Doz E, Rose S, Vasseur V, et al. 2007. IL-1 receptor-mediated signal is an essential component of MyD88-dependent innate response to Mycobacterium tuberculosis infection. J. Immunol. 179:1178-89
198. Mayer-BarberKD, Barber DL, Shenderov K, White SD, Wilson MS, et al. 2010. Caspase-1 independent IL-1βproduction is critical for host resistance to Mycobacterium tuberculosis and does not require TLR signaling in vivo. J. Immunol. 184:3326-30
199. De Libero G, Mori L. 2008. How T cells get grip on lipid antigens. Curr. Opin. Immunol. 20:96-104
200. Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB, Bloom BR. 1995. Natural and synthetic non-peptide antigens recognized by human γ∞T cells. Nature 375:155-58
201. Steinman RM. 2012. Decisions about dendritic cells: past, present, and future. Annu. Rev. Immunol. 30:1-22
202. Tailleux L, Schwartz O, Herrmann JL, Pivert E, Jackson M, et al. 2003. DC-SIGN is the major Mycobacterium tuberculosis receptor on human dendritic cells. J. Exp. Med. 197:121-27
203. + T cell response to Mycobacterium tuberculosis and exacerbates the outcome of infection. J. Immunol. 175:3268-72
204. Urdahl KB, Shafiani S, Ernst JD. 2011. Initiation and regulation of T-cell responses in tuberculosis. Mucosal Immunol. 4:288-93
205. Winslow GM, Cooper A, Reiley W, Chatterjee M, Woodland DL. 2008. Early T-cell responses in tuberculosis immunity. Immunol. Rev. 225:284-99
206. + T cells after airborne M. tuberculosis infection. J. Exp. Med. 205:2359-68
207. Reiley WW, Calayag MD, Wittmer ST, Huntington JL, Pearl JE, et al. 2008. ESAT-6-specific CD4 T cell responses to aerosol Mycobacterium tuberculosis infection are initiated in the mediastinal lymph nodes. Proc. Natl. Acad. Sci. USA 105:10961-66
208. Wolf AJ, Desvignes L, Linas B, Banaiee N, Tamura T, et al. 2008. Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J. Exp. Med. 205:105-15
209. Jung YJ, Ryan L, LaCourse R, North RJ. 2005. Properties and protective value of the secondary versus primary T helper type 1 response to airborne Mycobacterium tuberculosis infection in mice. J. Exp. Med. 201:1915-24
210. Kursar M, Koch M, Mittrucker HW, Nouailles G, Bonhagen K, et al. 2007. Cutting edge: regulatory T cells prevent efficient clearance of Mycobacterium tuberculosis. J. Immunol. 178:2661-65
211. Scott-Browne JP, Shafiani S, Tucker-Heard G, Ishida-Tsubota K, Fontenot JD, et al. 2007. Expansion and function of Foxp3-expressing T regulatory cells during tuberculosis. J. Exp. Med. 204:2159-69
212. Redford PS, Murray PJ, O'Garra A. 2011. The role of IL-10 in immune regulation during M. tuberculosis infection. Mucosal Immunol. 4:261-70
213. Brigl M, Brenner MB. 2004. CD1: antigen presentation and T cell function. Annu. Rev. Immunol. 22:817-90
214. De Libero G, Mori L. 2005. Recognition of lipid antigens by T cells. Nat. Rev. Immunol. 5:485-96
215. + T cells. Nature 372:691-94
216. Kasmar AG, van Rhijn I, Cheng T-Y, Turner M, Seshadri C, et al. 2011. CD1b tetramers bind αβ T cell receptors to identify a mycobacterial glycolipid-reactive T cell repertoire in humans. J. Exp. Med. 208:1741-47
217. Moody DB, Ulrichs T, Muhlecker W, Young DC, Gurcha SS, et al. 2000. CD1c-mediated T-cell recognition of isoprenoid glycolipids in Mycobacterium tuberculosis infection. Nature 404:884-88
218. Moody DB, Young DC, Cheng TY, Rosat JP, Roura-Mir C, et al. 2004. T cell activation by lipopeptide antigens. Science 303:527-31
219. Felio K, Nguyen H, Dascher CC, Choi H-J, Li S, et al. 2009. CD1-restricted adaptive immune responses to Mycobacteria in human group 1 CD1 transgenic mice. J. Exp. Med. 206:2497-509
220. Maglione PJ, Chan J. 2009. How B cells shape the immune response against Mycobacterium tuberculosis. Eur. J. Immunol. 39:676-86
221. Phuah JY, Mattila JT, Lin PL, Flynn JL. 2012. Activated B cells in the granulomas of nonhuman primates infected with Mycobacterium tuberculosis. Am. J. Pathol. 181:508-14
222. Bosio CM, Gardner D, Elkins KL. 2000. Infection of B cell-deficient mice with CDC 1551, a clinical isolate of Mycobacterium tuberculosis: delay in dissemination and development of lung pathology. J. Immunol. 164:6417-25
223. Maglione PJ, Xu J, Chan J. 2007. B cells moderate inflammatory progression and enhance bacterial containment upon pulmonary challenge with Mycobacterium tuberculosis. J. Immunol. 178:7222-34
224. Maglione PJ, Xu J, Casadevall A, Chan J. 2008. Fcγreceptors regulate immune activation and susceptibility during Mycobacterium tuberculosis infection. J. Immunol. 180:3329-38
225. CooperAM, Dalton DK, Stewart TA, Griffin JP, RussellDG, Orme IM. 1993. Disseminated tuberculosis in interferon γgene-disrupted mice. J. Exp. Med. 178:2243-47
226. Khader SA, Partida-Sanchez S, Bell G, Jelley-Gibbs DM, Swain S, et al. 2006. Interleukin 12p40 is required for dendritic cell migration and T cell priming after Mycobacterium tuberculosis infection. J. Exp. Med. 203:1805-15
227. Feng CG, Jankovic D, KullbergM, Cheever A, Scanga CA, et al. 2005. Maintenance of pulmonary Th1 effector function in chronic tuberculosis requires persistent IL-12 production. J. Immunol. 174:4185-92
228. Cooper AM, Kipnis A, Turner J, Magram J, Ferrante J, Orme IM. 2002. Mice lacking bioactive IL-12 can generate protective, antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present. J. Immunol. 168:1322-27
229. Holscher C, Atkinson RA, Arendse B, Brown N, Myburgh E, et al. 2001. A protective and agonistic function of IL-12p40 in mycobacterial infection. J. Immunol. 167:6957-66
230. Cooper AM, Adams LB, Dalton DK, Appelberg R, Ehlers S. 2002. IFN-γ and NO in mycobacterial disease: new jobs for old hands. Trends Microbiol. 10:221-26
231. WozniakTM, Ryan AA, BrittonWJ. 2006. Interleukin-23 restores immunity to Mycobacterium tuberculosis infection in IL-12p40-deficient mice and is not required for the development of IL-17-secreting T cell responses. J. Immunol. 177:8684-92
232. Khader SA, Pearl JE, Sakamoto K, Gilmartin L, Bell GK, et al. 2005. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-γresponses if IL-12p70 is available. J. Immunol. 175:788-95
233. Casanova JL, Abel L. 2002. Genetic dissection of immunity to mycobacteria: the human model. Annu. Rev. Immunol. 20:581-620
234. Doffinger R, Patel S, Kumararatne DS. 2005. Human immunodeficiencies that predispose to intracellular bacterial infections. Curr. Opin. Rheumatol. 17:440-46
235. Dorman S, Picard C, Lammas D, Heyne K, Vandissel J, et al. 2004. Clinical features of dominant and recessive interferon γreceptor 1 deficiencies. Lancet 364:2113-21
236. Jouanguy E, Lamhamedi-Cherradi S, Altare F, Fondaneche MC, Tuerlinckx D, et al. 1997. Partial interferon-γreceptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guerin infection and a sibling with clinical tuberculosis. J. Clin. Investig. 100:2658-64
237. Altare F, Ensser A, Breiman A, Reichenbach J, Baghdadi JE, et al. 2001. Interleukin-12 receptor β1 deficiency in a patient with abdominal tuberculosis. J. Infect. Dis. 184:231-36
238. Boisson-Dupuis S, ElBaghdadi J, ParvanehN, BousfihaA, Bustamante J, et al. 2011. IL-12Rβ1 deficiency in two of fifty children with severe tuberculosis from Iran, Morocco, and Turkey. PLoS ONE 6:e18524
239. Caragol I, Raspall M, Fieschi C, Feinberg J, Larrosa MN, et al. 2003. Clinical tuberculosis in 2 of 3 siblings with interleukin-12 receptor β1 deficiency. Clin. Infect. Dis. 37:302-6
240. Ozbek N, Fieschi C, Yilmaz BT, de Beaucoudrey L, Demirhan B, et al. 2005. Interleukin-12 receptor β1 chain deficiency in a child with disseminated tuberculosis. Clin. Infect. Dis. 40:e55-58
241. Bustamante J, Arias AA, Vogt G, Picard C, Galicia LB, et al. 2011. Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease. Nat. Immunol. 12:213-21
242. Marquis JF, LaCourse R, Ryan L, North RJ, Gros P. 2009. Disseminated and rapidly fatal tuberculosis in mice bearing a defective allele at IFN regulatory factor 8. J. Immunol. 182:3008-15
243. Bogunovic D, Byun M, Durfee LA, Abhyankar A, SanalO, et al. 2012. Mycobacterial disease and impaired IFN-γimmunity in humans with inherited ISG15 deficiency. Science 31:537-39
244. Tabarsi P, Marjani M, Mansouri N, Farnia P, Boisson-Dupuis S, et al. 2011. Lethal tuberculosis in a previously healthy adult with IL-12 receptor deficiency. J. Clin. Immunol. 31:537-39
245. Baghdadi JE, Orlova M, Alter A, Ranque B, Chentoufi M, et al. 2006. An autosomal dominant major gene confers predisposition to pulmonary tuberculosis in adults. J. Exp. Med. 203:1679-84
246. O'Garra AB, Britton WJ. 2008. Cytokines in tuberculosis. In Handbook of Tuberculosis: Immunology and Cell Biology, ed. SHE Kaufmann, WJ Britton, 2:185-225. Weinheim:Wiley-VCH
247. Tsao TC, Huang CC, Chiou WK, Yang PY, Hsieh MJ, Tsao KC. 2002. Levels of interferon-γ and interleukin-2 receptor-αfor bronchoalveolar lavage fluid and serum were correlated with clinical grade and treatment of pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 6:720-27
248. Vankayalapati R, Wizel B, Weis SE, Klucar P, Shams H, et al. 2003. Serum cytokine concentrations do not parallel Mycobacterium tuberculosis-induced cytokine production in patients with tuberculosis. Clin. Infect. Dis. 36:24-28
249. Verbon A, Juffermans N, Van Deventer SJ, Speelman P, Van Deutekom H, Van Der Poll T. 1999. Serum concentrations of cytokines in patients with active tuberculosis (TB) and after treatment. Clin. Exp. Immunol. 115:110-13
250. Barnes PF, Lu S, Abrams JS, Wang E, Yamamura M, Modlin RL. 1993. Cytokine production at the site of disease in human tuberculosis. Infect. Immun. 61:3482-89
251. Bhattacharyya S, Singla R, Dey AB, Prasad HK. 1999. Dichotomy of cytokine profiles in patients and high-risk healthy subjects exposed to tuberculosis. Infect. Immun. 67:5597-603
252. Hirsch CS, Toossi Z, Vanham G, Johnson JL, Peters P, et al. 1999. Apoptosis and T cell hyporesponsiveness in pulmonary tuberculosis. J. Infect. Dis. 179:945-53
253. + T cells in response to Mycobacterium tuberculosis in tuberculosis patients. Tuberculosis 82:7-13
254. Song CH, Kim HJ, Park JK, Lim JH, Kim UO, et al. 2000. Depressed interleukin-12 (IL-12), but not IL-18, production in response to a 30-or 32-kilodalton mycobacterial antigen in patients with active pulmonary tuberculosis. Infect. Immun. 68:4477-84
255. Torres M, Herrera T, Villareal H, Rich EA, Sada E. 1998. Cytokine profiles for peripheral blood lymphocytes from patients with active pulmonary tuberculosis and healthy household contacts in response to the 30-kilodalton antigen of Mycobacterium tuberculosis. Infect. Immun. 66:176-80
256. Vekemans J, Lienhardt C, Sillah JS, Wheeler JG, Lahai GP, et al. 2001. Tuberculosis contacts but not patients have higher γ interferon responses to ESAT-6 than do community controls in The Gambia. Infect. Immun. 69:6554-57
257. Pathan AA, Wilkinson KA, Klenerman P, McShane H, Davidson RN, et al. 2001. Direct ex vivo analysis of antigen-specific IFN-γ-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J. Immunol. 167:5217-25
258. Sodhi A, Gong J, Silva C, Qian D, Barnes PF. 1997. Clinical correlates of interferon γ production in patients with tuberculosis. Clin. Infect. Dis. 25:617-20
259. Hirsch CS, Toossi Z, Othieno C, Johnson JL, Schwander SK, et al. 1999. Depressed T-cell interferon-γ responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy. J. Infect. Dis. 180:2069-73
260. Cardoso FL, Antas PR, Milagres AS, Geluk A, Franken KL, et al. 2002. T-cell responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 in Brazilian tuberculosis patients. Infect. Immun. 70:6707-14
261. DlugovitzkyD, Bay ML, RateniL, FiorenzaG, Vietti L, et al. 2000. Influence of disease severity on nitrite and cytokine production by peripheral blood mononuclear cells (PBMC) from patients with pulmonary tuberculosis (TB). Clin. Exp. Immunol. 122:343-49
262. Surcel HM, Troye-Blomberg M, Paulie S, Andersson G, Moreno C, et al. 1994. Th1/Th2 profiles in tuberculosis, based on the proliferation and cytokine response of blood lymphocytes to mycobacterial antigens. Immunology 81:171-76
263. Winkler S, Necek M, Winkler H, Adegnika AA, Perkmann T, et al. 2005. Increased specific T cell cytokine responses in patients with active pulmonary tuberculosis from Central Africa. Microbes Infect. 7:1161-69
264. VordermeierHM, Chambers MA, Cockle PJ, Whelan AO, Simmons J, Hewinson RG. 2002. Correlation of ESAT-6-specific γinterferon production with pathology in cattle following Mycobacterium bovis BCG vaccination against experimental bovine tuberculosis. Infect. Immun. 70:3026-32
265. Zea AH, Ochoa MT, Ghosh P, Longo DL, Alvord WG, et al. 1998. Changes in expression of signal transduction proteins in T lymphocytes of patients with leprosy. Infect. Immun. 66:499-504
266. Baliko Z, Szereday L, Szekeres-Bartho J. 1998. Th2 biased immune response in cases with active Mycobacterium tuberculosis infection and tuberculin anergy. FEMS Immunol. Med. Microbiol. 22:199-204
267. Boussiotis VA, Tsai EY, Yunis EJ, Thim S, Delgado JC, et al. 2000. IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J. Clin. Investig. 105:1317-25
268. Nash DR, Douglass JE. 1980. Anergy in active pulmonary tuberculosis. A comparison between positive and negative reactors and an evaluation of 5 TU and 250 TU skin test doses. Chest 77:32-37
269. Zea AH, Culotta KS, Ali J, Mason C, Park HJ, et al. 2006. Decreased expression of CD3 and nuclear transcription factor κB in patients with pulmonary tuberculosis: potential mechanisms and reversibility with treatment. J. Infect. Dis. 194:1385-93
270. BoehmU, KlampT, Groot M, Howard JC. 1997. Cellular responses to interferon-γ. Annu. Rev. Immunol. 15:749-95
271. MacMicking JD, North RJ, LaCourse R, Mudgett JS, Shah SK, Nathan CF. 1997. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc. Natl. Acad. Sci. USA. 94:5243-48
272. Scanga CA, Mohan VP, Tanaka K, Alland D, Flynn JL, Chan J. 2001. The inducible nitric oxide synthase locus confers protection against aerogenic challenge of both clinical and laboratory strains of Mycobacterium tuberculosis in mice. Infect. Immun. 69:7711-17
273. Choi HS, Rai PR, Chu HW, Cool C, Chan ED. 2002. Analysis of nitric oxide synthase and nitrotyrosine expression in human pulmonary tuberculosis. Am. J. Respir. Crit. CareMed. 166:178-86
274. Nathan C, Shiloh MU. 2000. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc. Natl. Acad. Sci. USA 97:8841-48
275. MacMicking JD, Taylor GA, McKinney JD. 2003. Immune control of tuberculosis by IFN-γ-inducible LRG-47. Science 302:654-59
276. + T cell populations by preventing interferon-γ-induced cell death. Nat. Immunol. 9:1279-87
277. Russell DG, VanderVen BC, Lee W, Abramovitch RB, Kim MJ, et al. 2010. Mycobacterium tuberculosis wears what it eats. Cell Host Microbe 8:68-76
278. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. 2008. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26:677-704
279. Jurado JO, Alvarez IB, Pasquinelli V, Martinez GJ, Quiroga MF, et al. 2008. Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J. Immunol. 181:116-25
280. McNab FW, Berry MP, Graham CM, Bloch SA, Oni T, et al. 2011. Programmed death ligand 1 is overexpressed by neutrophils in the blood of patients with active tuberculosis. Eur. J. Immunol. 41:1941-47
281. Barber DL, Mayer-Barber KD, Antonelli LR, Wilson MS, White S, et al. 2010. Th1-driven immune reconstitution disease in Mycobacterium avium-infected mice. Blood 116:3485-93
282. Lazar-Molnar E, Chen B, Sweeney KA, Wang EJ, Liu W, et al. 2010. Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proc. Natl. Acad. Sci. USA 107:13402-7
283. Cruz A, Khader SA, Torrado E, Fraga A, Pearl JE, et al. 2006. Cutting edge: IFN-γ regulates the induction and expansion of IL-17-producing CD4 T cells during mycobacterial infection. J. Immunol. 177:1416-20
284. Lockhart E, Green AM, Flynn JL. 2006. IL-17 production is dominated by γ∞T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J. Immunol. 177:4662-69
285. Umemura M, Yahagi A, Hamada S, Begum MD, WatanabeH, et al. 2007. IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection. J. Immunol. 178:3786-96
286. Okamoto Yoshida Y, Umemura M, Yahagi A, O'Brien RL, Ikuta K, et al. 2010. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J. Immunol. 184:4414-22
287. + Tcell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat. Immunol. 8:369-77
288. Gopal R, Lin Y, Obermajer N, Slight S, Nuthalapati N, et al. 2012. IL-23-dependent IL-17 drives Th1-cell responses following Mycobacterium bovis BCG vaccination. Eur. J. Immunol. 42:364-73
289. Gallegos AM, van Heijst JW, Samstein M, Su X, Pamer EG, Glickman MS. 2011. A gamma interferon independentmechanism of CD4 T cell mediated control of M. tuberculosis infection in vivo. PLoS Pathog. 7:e1002052
290. Saraiva M, O'Garra A. 2010. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 10:170-81
291. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. 1991. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147:3815-22
292. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, et al. 1991. IL-10 acts on the antigenpresenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 146:3444-51
293. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19:683-765
294. Bogdan C, Vodovotz Y, Nathan C. 1991. Macrophage deactivation by interleukin 10. J. Exp. Med. 174:1549-55
295. Almeida AS, Lago PM, Boechat N, Huard RC, Lazzarini LC, et al. 2009. Tuberculosis is associated with a down-modulatory lung immune response that impairs Th1-type immunity. J. Immunol. 183:718-31
296. Huard RC, Chitale S, Leung M, Lazzarini LC, Zhu H, et al. 2003. The Mycobacterium tuberculosis complex-restricted gene cfp32 encodes an expressed protein that is detectable in tuberculosis patients and is positively correlated with pulmonary interleukin-10. Infect. Immun. 71:6871-83
297. Bonecini-AlmeidaMG, Ho JL, Boechat N, Huard RC, Chitale S, et al. 2004. Down-modulation of lung immune responses by interleukin-10 and transforming growth factor β(TGF-β) and analysis of TGF-β receptors I and II in active tuberculosis. Infect. Immun. 72:2628-34
298. + T-cell responses to Mycobacterium tuberculosis by interleukin-10 and transforming growth factor β. Infect. Immun. 67:6461-72
299. Gong JH, Zhang M, Modlin RL, Linsley PS, Iyer D, et al. 1996. Interleukin-10 downregulates Mycobacterium tuberculosis-induced Th1 responses and CTLA-4 expression. Infect. Immun. 64:913-18
300. ZhangM, Gong J, IyerDV, Jones BE, Modlin RL, Barnes PF. 1994.T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection. J. Clin. Investig. 94:2435-42
301. + Tcell clones producing both interferon-γand interleukin-10 predominate in bronchoalveolar lavages of active pulmonary tuberculosis patients. Clin. Immunol. 92:224-34
302. Awomoyi AA, Marchant A, Howson JM, McAdam KP, Blackwell JM, Newport MJ. 2002. Interleukin-10, polymorphism in SLC11A1 (formerly NRAMP1), and susceptibility to tuberculosis. J. Infect. Dis. 186:1808-14
303. +874T/A, IL10 -1082G/A and TNF -308G/A polymorphisms in association with tuberculosis susceptibility: ameta-analysis study. Hum. Genet. 123:477-84
304. Zhang J, ChenY, Nie XB, WuWH, ZhangH, et al. 2011. Interleukin-10 polymorphisms and tuberculosis susceptibility: a meta-analysis. Int. J. Tuberc. Lung Dis. 15:594-601
305. Jung YJ, Ryan L, LaCourse R, North RJ. 2003. Increased interleukin-10 expression is not responsible for failure ofThelper 1 immunity to resolve airborne Mycobacterium tuberculosis infection inmice. Immunology 109:295-99
306. North RJ. 1998. Mice incapable of making IL-4 or IL-10 display normal resistance to infection with Mycobacterium tuberculosis. Clin. Exp. Immunol. 113:55-58
307. Beamer GL, Flaherty DK, Assogba BD, Stromberg P, Gonzalez-Juarrero M, et al. 2008. Interleukin-10 promotes Mycobacterium tuberculosis disease progression in CBA/J mice. J. Immunol. 181:5545-50
308. Turner J, Gonzalez-Juarrero M, Ellis DL, Basaraba RJ, Kipnis A, et al. 2002. In vivo IL-10 production reactivates chronic pulmonary tuberculosis in C57BL/6 mice. J. Immunol. 169:6343-51
309. Higgins DM, Sanchez-Campillo J, Rosas-Taraco AG, Lee EJ, Orme IM, Gonzalez-Juarrero M. 2009. Lack of IL-10 alters inflammatory and immune responses during pulmonary Mycobacterium tuberculosis infection. Tuberculosis 89:149-57
310. Roach DR, Martin E, Bean AG, Rennick DM, Briscoe H, Britton WJ. 2001. Endogenous inhibition of antimycobacterial immunity by IL-10 varies between mycobacterial species. Scand. J. Immunol. 54:163-70
311. Demangel C, Bertolino P, Britton WJ. 2002. Autocrine IL-10 impairs dendritic cell (DC)-derived immune responses to mycobacterial infection by suppressing DC trafficking to draining lymph nodes and local IL-12 production. Eur. J. Immunol. 32:994-1002
312. O'Leary S, O'Sullivan MP, Keane J. 2011. IL-10 blocks phagosome maturation in Mycobacterium tuberculosis-infected human macrophages. Am. J. Respir. Cell Mol. Biol. 45:172-80
313. Shaw TC, Thomas LH, Friedland JS. 2000. Regulation of IL-10 secretion after phagocytosis of Mycobacterium tuberculosis by human monocytic cells. Cytokine 12:483-86
314. Schreiber T, Ehlers S, Heitmann L, Rausch A, Mages J, et al. 2009. Autocrine IL-10 induces hallmarks of alternative activation in macrophages and suppresses antituberculosis effector mechanisms without compromising T cell immunity. J. Immunol. 183:1301-12
315. + and Foxp3-precursor cells in the absence of interleukin Nat. Immunol. 8:931-41
316. Ordway D, Henao-Tamayo M, Harton M, Palanisamy G, Troudt J, et al. 2007. The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation. J. Immunol. 179:522-31
317. Newton SM, Smith RJ, Wilkinson KA, NicolMP, Garton NJ, et al. 2006. A deletion defining a common Asian lineage of Mycobacterium tuberculosis associates with immune subversion. Proc. Natl. Acad. Sci. USA 103:15594-98
318. Pitt JM, Stavropoulos E, Redford PS, Beebe AM, Bancroft GJ, et al. 2012. Blockade of IL-10 signaling during bacillus Calmette-Guerin vaccination enhances and sustains Th1, Th17, and innate lymphoid IFN-γand IL-17 responses and increases protection to Mycobacterium tuberculosis infection. J. Immunol. 189:4079-87
319. Elias D, Britton S, Aseffa A, Engers H, Akuffo H. 2008. Poor immunogenicity of BCG in helminth infected population is associated with increased in vitro TGF-βproduction. Vaccine 26:3897-902
320. Resende Co T, Hirsch CS, Toossi Z, Dietze R, Ribeiro-Rodrigues R. 2007. Intestinal helminth coinfection has a negative impact on both anti-Mycobacterium tuberculosis immunity and clinical response to tuberculosis therapy. Clin. Exp. Immunol. 147:45-52
321. Babu S, Bhat SQ, Kumar NP, Jayantasri S, Rukmani S, et al. 2009. Human type 1 and 17 responses in latent tuberculosis are modulated by coincident filarial infection through cytotoxic T lymphocyte antigen-4 and programmed death-1. J. Infect. Dis. 200:288-98
322. Potian JA, Rafi W, Bhatt K, McBride A, Gause WC, Salgame P. 2011. Preexisting helminth infection induces inhibition of innate pulmonary anti-tuberculosis defense by engaging the IL-4 receptor pathway. J. Exp. Med. 208:1863-74
323. Trinchieri G. 2010. Type I interferon: friend or foe? J. Exp. Med. 207:2053-63
324. Cooper AM, Pearl JE, Brooks JV, Ehlers S, Orme IM. 2000. Expression of the nitric oxide synthase 2 gene is not essential for early control of Mycobacterium tuberculosis in the murine lung. Infect. Immun. 68:6879-82
325. Stanley SA, Johndrow JE, Manzanillo P, Cox JS. 2007. The type I IFN response to infection with Mycobacterium tuberculosis requires ESX-1-mediated secretion and contributes to pathogenesis. J. Immunol. 178:3143-52
326. Antonelli LR, Gigliotti Rothfuchs A, Goncalves R, Roffe E, Cheever AW, et al. 2010. Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. J. Clin. Investig. 120:1674-82
327. Kaiser F, Cook D, Papoutsopoulou S, Rajsbaum R, Wu X, et al. 2009. TPL-2 negatively regulates interferon-βproduction in macrophages and myeloid dendritic cells. J. Exp. Med. 206:1863-71
328. Pandey AK, Yang Y, Jiang Z, Fortune SM, Coulombe F, et al. 2009. NOD2, RIP2 and IRF5 play a critical role in the type I interferon response to Mycobacterium tuberculosis. PLoS Pathog. 5:e1000500
329. Novikov A, CardoneM, Thompson R, Shenderov K, Kirschman KD, et al. 2011. Mycobacterium tuberculosis triggers host type I IFN signaling to regulate IL-1βproduction in human macrophages. J. Immunol. 187:2540-47
330. Mayer-BarberKD, Andrade BB, Barber DL, Hieny S, Feng CG, et al. 2011. Innate and adaptive interferons suppress IL-1αand IL-1βproduction by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity 35:1023-34
331. Mariotti S, Teloni R, Iona E, Fattorini L, Romagnoli G, et al. 2004. Mycobacterium tuberculosis diverts α interferon-induced monocyte differentiation from dendritic cells into immunoprivileged macrophagelike host cells. Infect. Immun. 72:4385-92
332. Reed MB, Domenech P, Manca C, Su H, Barczak AK, et al. 2004. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature 431:84-87
333. Portevin D, Gagneux S, Comas I, Young D. 2011. Human macrophage responses to clinical isolates from the Mycobacterium tuberculosis complex discriminate between ancient and modern lineages. PLoS Pathog. 7:e1001307
334. Filliol I, Motiwala AS, CavatoreM, QiW, Hazbon MH, et al. 2006. Global phylogeny of Mycobacterium tuberculosis based on single nucleotide polymorphism (SNP) analysis: insights into tuberculosis evolution, phylogenetic accuracy of other DNA fingerprinting systems, and recommendations for a minimal standard SNP set. J. Bacteriol. 188:759-72
335. Tsenova L, Ellison E, Harbacheuski R, Moreira AL, Kurepina N, et al. 2005. Virulence of selected Mycobacterium tuberculosis clinical isolates in the rabbit model of meningitis is dependent on phenolic glycolipid produced by the bacilli. J. Infect. Dis. 192:98-106
336. Sinsimer D, Huet G, Manca C, Tsenova L, Koo MS, et al. 2008. The phenolic glycolipid of Mycobacterium tuberculosis differentially modulates the early host cytokine response but does not in itself confer hypervirulence. Infect. Immun. 76:3027-36
337. KooMS, Subbian S, Kaplan G. 2012. Strain specific transcriptional response in Mycobacterium tuberculosis infected macrophages. Cell Commun. Signal. 10:2
338. Schutz C, Meintjes G, Almajid F, Wilkinson RJ, Pozniak A. 2010. Clinical management of tuberculosis and HIV-1 co-infection. Eur. Respir. J. 36:1460-81
339. Rangaka MX, Gideon HP, Wilkinson KA, Pai M, Mwansa-Kambafwile J, et al. 2012. Interferon release does not add discriminatory value to smear-negative HIV-tuberculosis algorithms. Eur. Respir. J. 39:163-71
340. Johnson JL, Nyole S, Okwera A, Whalen CC, Nsubuga P, et al. 1998. Instability of tuberculin and candida skin test reactivity in HIV-infected Ugandans. Am. J. Respir. Crit. Care Med. 158:1790-96
341. Rangaka MX, Wilkinson KA, Seldon R, Van Cutsem G, Meintjes GA, et al. 2007. Effect of HIV-1 infection on T-cell-based and skin test detection of tuberculosis infection. Am. J. Respir. Crit. CareMed. 175:514-20
342. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, et al. 2008. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect. Dis. 8:516-23
343. Mukadi Y, Perriens JH, St Louis ME, Brown C, Prignot J, et al. 1993.
344. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. 2005. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J. Infect. Dis. 191:150-58
345. Kalsdorf B, Scriba TJ, Wood K, Day CL, Dheda K, et al. 2009. HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria. Am. J. Respir. Crit. CareMed. 180:1262-70
346. + memory T-cell phenotype at the site of disease in extrapulmonary tuberculosis. Eur. J. Immunol. 42:147-57
347. Hill AR, Premkumar S, Brustein S, Vaidya K, Powell S, et al. 1991. Disseminated tuberculosis in the acquired immunodeficiency syndrome era. Am. Rev. Respir. Dis. 144:1164-70
348. Mattila JT, Diedrich CR, Lin PL, Phuah J, Flynn JL. 2011. Simian immunodeficiency virus-induced changes in T cell cytokine responses in cynomolgus macaques with latent Mycobacterium tuberculosis infection are associated with timing of reactivation. J. Immunol. 186:3527-37
349. Pathak S, Wentzel-Larsen T, Asjo B. 2010. Effects of in vitro HIV-1 infection on mycobacterial growth in peripheral blood monocyte-derived macrophages. Infect. Immun. 78:4022-32
350. Meylan PR, Munis JR, Richman DD, Kornbluth RS. 1992. Concurrent human immunodeficiency virus and mycobacterial infection of macrophages in vitro does not reveal any reciprocal effect. J. Infect. Dis. 165:80-86
351. Reuter MA, PecoraND, Harding CV, CanadayDH, McDonald D. 2010. Mycobacterium tuberculosis promotes HIV trans-infection and suppresses major histocompatibility complex class II antigen processing by dendritic cells. J. Virol. 84:8549-60
352. Campbell GR, Spector SA. 2012. VitaminDinhibits human immunodeficiency virus type 1 and Mycobacterium tuberculosis infection inmacrophages through the induction of autophagy. PLoS Pathog. 8:e1002689
353. Hoshino Y, Tse DB, RochfordG, Prabhakar S, Hoshino S, et al. 2004. Mycobacterium tuberculosis-induced CXCR4 and chemokine expression leads to preferential X4 HIV-1 replication in human macrophages. J. Immunol. 172:6251-58
354. Toossi Z, Johnson JL, Kanost RA, Wu M, Luzze H, et al. 2001. Increased replication of HIV-1 at sites of Mycobacterium tuberculosis infection: potential mechanisms of viral activation. J. Acquir. Immune Defic. Syndr. 28:1-8
355. Hoshino Y, Hoshino S, Gold JA, Raju B, Prabhakar S, et al. 2007. Mechanisms of polymorphonuclear neutrophil-mediated induction of HIV-1 replication in macrophages during pulmonary tuberculosis. J. Infect. Dis. 195:1303-10
356. Hoshino Y, Nakata K, Hoshino S, Honda Y, Tse DB, et al. 2002. Maximal HIV-1 replication in alveolar macrophages during tuberculosis requires both lymphocyte contact and cytokines. J. Exp. Med. 195:495-505
357. Toossi Z, Wu M, Hirsch CS, Mayanja-Kizza H, Baseke J, et al. 2012. Activation of P-TEFb at sites of dual HIV/TB infection, and inhibition of MTB-induced HIV transcriptional activation by the inhibitor of CDK9, Indirubin-3-monoxime. AIDS Res. Hum. Retrovir. 28:182-87
358. + T cells specific for tuberculosis correlate with improved clinical immunity after highly active antiretroviral therapy. AIDS Res. Hum. Retrovir. 18:969-75
359. + T cell responses to tuberculosis antigens in HIV-1-infected patients before and after antiretroviral treatment. J. Immunol. 184:6537-44
360. Wilkinson KA, Seldon R, Meintjes G, RangakaMX, HanekomWA, et al. 2009. Dissection of regenerating T-cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis. Am. J. Respir. Crit. CareMed. 180:674-83
361. Meintjes G, Rabie H, Wilkinson RJ, Cotton MF. 2009. Tuberculosis- associated immune reconstitution inflammatory syndrome and unmasking of tuberculosis by antiretroviral therapy. Clin. Chest Med. 30:797-810
362. Narita M, AshkinD, Hollender ES, Pitchenik AE. 1998. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am. J. Respir. Crit. CareMed. 158:157-61
363. Bourgarit A, Carcelain G, Martinez V, Lascoux C, Delcey V, et al. 2006. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 20:F1-7
364. Meintjes G, Skolimowska KH, Wilkinson KA, Matthews K, Tadokera R, et al. 2012. Corticosteroid modulated immune activation in the TB immune reconstitution inflammatory syndrome. Am. J. Respir. Crit. Care Med. 186:369-77
365. Meintjes G, Wilkinson KA, Rangaka MX, Skolimowska K, van Veen K, et al. 2008. Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis- associated immune reconstitution inflammatory syndrome. Am. J. Respir. Crit. CareMed. 178:1083-89
366. + T-cell responses in HIVpositive patients with mycobacterial immune restoration disease. Eur. J. Immunol. 39:391-403
367. Barber DL, Andrade BB, Sereti I, Sher A. 2012. Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none. Nat. Rev. Microbiol. 10:150-56
368. Lawn SD, Wainwright H, Orrell C. 2009. Fatal unmasking tuberculosis immune reconstitution disease with bronchiolitis obliterans organizing pneumonia: the role of macrophages. AIDS 23:143-45
369. Tadokera R, Meintjes G, Skolimowska KH, Wilkinson KA, Matthews K, et al. 2011. Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome. Eur. Respir. J. 37:1248-59
370. Bourgarit A, Carcelain G, Samri A, Parizot C, LafaurieM, et al. 2009. Tuberculosis-associated immune restoration syndrome in HIV-1-infected patients involves tuberculin-specific CD4 Th1 cells and KIRnegative γ∞T cells. J. Immunol. 183:3915-23
371. Pean P, Nerrienet E, Madec Y, Borand L, Laureillard D, et al. 2012. Natural killer cell degranulation capacity predicts early onset of the immune reconstitution inflammatory syndrome (IRIS) in HIVinfected patients with tuberculosis. Blood 119:3315-20
372. Round JL, Mazmanian SK. 2009. The gut microbiota shapes intestinal immune responses during health and disease. Nat. Rev. Immunol. 9:313-23
373. Karp CL. 2012. Unstressing intemperate models: how cold stress undermines mouse modeling. J. Exp. Med. 209:1069-74